Clinical Trials

2 studies in Urothelial Cancer

1. Longer-term Recurrence Rates in Patients With Bladder Cancer After Hexvix (Cysview)Fluorescence Cystoscopy/TURB Rochester, MN View Summary
   Close

   Longer-term Recurrence Rates in Patients With Bladder Cancer After Hexvix (Cysview)Fluorescence Cystoscopy/TURB

   Location:

   Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   A previously completed pivotal clinical study PC B305/04 demonstrated reduced recurrence rates for patients with papillary bladder cancer who underwent Hexvix (Cysview) and white light cystoscopy and transurethral resection (TURB) of the bladder compared to patients who underwent white light cystoscopy and TURB alone. The present study is intended to investigate whether the improved initial detection and resection of bladder cancer lesions in patients with non-muscle invasive bladder cancer with Hexvix (Cysview) fluorescence cystoscopy/TURB will also lead to a longer-term reduction in recurrences compared to standard white light cystoscopy/TURB.

   NCT ID:

   NCT01166230

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   - Mayo Clinic Cancer Center - Phone: 507-538-7623 - Research Volunteer Program - Phone: 1-800-664-4542 (toll-free) Email: clinicaltrials@mayo.edu - International Research - Phone: 507-284-8884 Email: intl.mcr@mayo.edu

   Request Information Online
2. DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma Scottsdale and Phoenix, AZ Rochester, MN View Summary
   Close

   DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma

   Location:

   Scottsdale and Phoenix, AZ Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   This is a multicenter, open-label, Phase 2 study. Subjects will be randomized to either the investigational product, DN24-02, or to standard of care. The purpose of this study is to compare the length of survival between these 2 groups of subjects. Other purposes of the study are to learn about the safety of DN24-02, to learn if it delays the time until urothelial cancer recurs, and to learn if the immune system responds to treatment with DN24-02. All subjects will be followed for this study for the remainder of their lives.

   NCT ID:

   NCT01353222

   IRB Number:

   11-008919

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   Rochester: Carol Van Oort, RN 507-284-3369
                       
   Scottsdale: Eric Siebeneck 480-301-6253
                       
   
   

   Request Information Online